LCTX

Company Overview — What Does Lineage Cell Therapeutics, Inc. Do?

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. Lineage Cell Therapeutics, Inc. (LCTX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Brian M. Culley and employs approximately 60 people, headquartered in CARLSBAD , California. With a market capitalization of $396M, LCTX is one of the notable companies in the Healthcare sector.

Lineage Cell Therapeutics, Inc. (LCTX) Stock Rating — Reduce (April 2026)

As of April 2026, Lineage Cell Therapeutics, Inc. receives a Reduce rating with a composite score of 36.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.LCTX ranks #3,052 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Lineage Cell Therapeutics, Inc. ranks #447 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

LCTX Stock Price and 52-Week Range

Lineage Cell Therapeutics, Inc. (LCTX) currently trades at $1.48. The stock lost $0.01 (0.7%) in the most recent trading session. The 52-week high for LCTX is $2.09, which means the stock is currently trading -29.2% from its annual peak. The 52-week low is $0.37, putting the stock 305.4% above its annual trough. Recent trading volume was 851K shares, suggesting relatively thin trading activity.

Is LCTX Overvalued or Undervalued? — Valuation Analysis

Lineage Cell Therapeutics, Inc. (LCTX) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 8.73x, versus the sector average of 2.75x. The price-to-sales ratio is 32.29x, compared to 1.66x for the average Healthcare stock.

At current multiples, Lineage Cell Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Lineage Cell Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Lineage Cell Therapeutics, Inc. (LCTX) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -155.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -59.7% versus the sector average of -33.1%.

On a margin basis, Lineage Cell Therapeutics, Inc. reports gross margins of 98.3%, compared to 71.5% for the sector. The operating margin is -338.2% (sector: -66.1%). Net profit margin stands at -565.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 161.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

LCTX Debt, Balance Sheet, and Financial Health

Lineage Cell Therapeutics, Inc. has a debt-to-equity ratio of 160.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 5.20x, indicating strong short-term liquidity. Total debt on the balance sheet is $83,000. Cash and equivalents stand at $40M.

LCTX has a beta of 1.10, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Lineage Cell Therapeutics, Inc. is 41/100, reflecting average volatility within the normal range for its sector.

Lineage Cell Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Lineage Cell Therapeutics, Inc. reported revenue of $12M and earnings per share (EPS) of $-0.28. Net income for the quarter was $-67M. Gross margin was 98.3%. Operating income came in at $-34M.

In FY 2025, Lineage Cell Therapeutics, Inc. reported revenue of $15M and earnings per share (EPS) of $-0.28. Net income for the quarter was $-63M. Revenue grew 53.2% year-over-year compared to FY 2024. Operating income came in at $-37M.

In Q3 2025, Lineage Cell Therapeutics, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-30M. Revenue grew -2.6% year-over-year compared to Q3 2024. Operating income came in at $-4M.

In Q2 2025, Lineage Cell Therapeutics, Inc. reported revenue of $3M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-30M. Revenue grew 96.4% year-over-year compared to Q2 2024. Operating income came in at $-20M.

Over the past 8 quarters, Lineage Cell Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $1M to $12M. Investors analyzing LCTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

LCTX Dividend Yield and Income Analysis

Lineage Cell Therapeutics, Inc. (LCTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

LCTX Momentum and Technical Analysis Profile

Lineage Cell Therapeutics, Inc. (LCTX) has a momentum factor score of 59/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 55/100 reflects moderate short selling activity.

LCTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Lineage Cell Therapeutics, Inc. (LCTX) ranks #447 out of 838 stocks based on the Blank Capital composite score. This places LCTX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing LCTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LCTX vs S&P 500 (SPY) comparison to assess how Lineage Cell Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

LCTX Next Earnings Date

No upcoming earnings date has been announced for Lineage Cell Therapeutics, Inc. (LCTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy LCTX? — Investment Thesis Summary

The quantitative profile for Lineage Cell Therapeutics, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 24/100 indicates premium valuation.

In summary, Lineage Cell Therapeutics, Inc. (LCTX) earns a Reduce rating with a composite score of 36.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LCTX stock.

Related Resources for LCTX Investors

Explore more research and tools: LCTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare LCTX head-to-head with peers: LCTX vs AZN, LCTX vs SLGL, LCTX vs VMD.